Drug Trial Radar · NCT00014222
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Last checked: Nov 20, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,104
Actual
Start
Dec 4, 2000
Primary completion
Feb 10, 2014
Study completion Mar 17, 2014
Sponsor
- Lead sponsor
- NCIC Clinical Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- North Central Cancer Treatment Group; SWOG Cancer Research Network; Cancer and Leukemia Group B
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Conditions
- Breast Cancer
Interventions
epoetin alfaBiological
40,000 IU
filgrastimBiological
5 mg/kg/d - days 2-13
cyclophosphamideDrug
75, 600 and 830 mg/m2
doxorubicin hydrochlorideDrug
60 mg/m2
epirubicin hydrochlorideDrug
60 mg/m2
fluorouracilDrug
500mg/m2
paclitaxelDrug
175 mg/m2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free SurvivalTime frame: 13 years
Locations
78 sites in 2 countries. Site status is shown where the registry gives one.
Sparks-Arkansas Oklahoma Cancer Treatment Centre
Fort Smith, Arkansas
Hematology Oncology Services of Arkansas
Little Rock, Arkansas
Scripps Cancer Center
La Jolla, California
University of Colorado Cancer Centre
Aurora, Colorado
Greenwich Hospital - Bendheim Cancer Center
Greenwich, Connecticut
Sibley Memorial Hospital, Oncology Research
Washington D.C., District of Columbia
Comprehensive Cancer Care Centre at Boca Raton
Boca Raton, Florida
University of Florida
Gainesville, Florida
Florida Oncology Associates
Orange Park, Florida
The University of Chicago Medical Center
Chicago, Illinois
Therapy Associates, Inc., Hematology/Oncology
Evansville, Indiana
Lexington Oncology Assts./Central Baptist Hospital
Lexington, Kentucky
Consultants in Blood Disorders and Cancer
Louisville, Kentucky
CHRISTUS Schumpert Medical Center - Hem/Onc Clinic
Shreveport, Louisiana
Willis-Knighton Cancer Center
Shreveport, Louisiana
Maine Center for Cancer Medicine and Blood Disorders
Scarborough, Maine
Maine General Medical Center
Waterville, Maine
Suburban Hospital Cancer Program
Bethesda, Maryland
Associates in Oncology/Hematology
Rockville, Maryland
Saint Joseph Medical Center, Cancer Care Program
Towson, Maryland
Baystate Regional Cancer Program
Springfield, Massachusetts
St. Luke's Cancer Care Centre
Duluth, Minnesota
University of Minnesota Cancer Centre
Minneapolis, Minnesota
Columbia-Capitol Comprehensive Care Clinics
Jefferson City, Missouri
Saint Louis University Hospital
St Louis, Missouri
Nebraska Methodist Hospital
Omaha, Nebraska
Creighton University Cancer Centre
Omaha, Nebraska
Advanced Oncology Associates
Armonk, New York
Queens Medical Associates, PC
Fresh Meadows, New York
Winthrop University Hospital Onc/Hem
Mineola, New York
Hematology Oncol. Associates Rockland
Nyack, New York
University of Rochester
Rochester, New York
Staten Island University Hospital
Staten Island, New York
Our Lady of Mercy Medical Center
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
ECU School of Medicine, Leo Jenkins Cancer Center
Greenville, North Carolina
Oncology/Hematology Care, Inc.
Cincinnati, Ohio
Pottstown Memorial Regional Cancer Centre
Pottstown, Pennsylvania
Santee Hematology Oncology
Sumter, South Carolina
University Oncology and Hematology Associates
Chattanooga, Tennessee
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.